The Future of Triple-Negative Breast Cancer Treatment Includes Immunotherapy Combinations – Curetoday.com
Curetoday.com |
The Future of Triple-Negative Breast Cancer Treatment Includes Immunotherapy Combinations
Curetoday.com Single-agent immunotherapy has demonstrated a modest clinical response in pretreated patients. The findings of the phase 2 KEYNOTE-086 trial showed that Keytruda (pembrolizumab) had antitumor activity in patients with heavily pretreated metastatic … |
